Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania
February 23 2017 - 7:58AM
Business Wire
Collaboration aims to advance the understanding
of cancer biology and foster innovative science in
immunotherapy
Incyte Corporation (Nasdaq:INCY) today announces a multi-year
research collaboration with the Abramson Cancer Center at the
University of Pennsylvania. Through this collaboration, Incyte and
Abramson have agreed to bring together the knowledge and expertise
of their leading drug discovery and development scientists to
conduct collaborative research aimed at advancing the understanding
of cancer biology and fostering innovative science in
immunotherapy.
Under the collaboration, Penn investigators will leverage their
expertise in preclinical biology and translational science to
investigate the novel therapeutics being discovered at Incyte and
better understand their mechanisms of action—further developing the
clinical rationales for combination therapy and patient selection.
Additionally, in a combined effort to better define the
relationships between human tumor characteristics and immune cell
infiltration and function, Incyte and Penn will work together to
develop a bioinformatics program in clinical immunotherapy aimed at
fostering the advancement of novel therapeutics.
During the period of the collaboration, Incyte will provide
financial support for these research programs and may also conduct
additional grant-funded research with Penn investigators in other
innovative areas of cancer immunology.
“Incyte and Abramson are mutually committed to the advancement
of science and improving the lives of patients with cancer. This
alliance will allow us to mobilize two groups of leading scientists
toward the collective goal of advancing the field of
immunotherapy,” said Reid Huber, Ph.D., Chief Scientific Officer at
Incyte. “We are excited for the opportunity to partner with the
world-class researchers at Abramson and investigate new avenues for
the treatment of patients with cancer.”
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company’s website at
www.incyte.com.
Follow @Incyte on Twitter
at https://twitter.com/Incyte.
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release – including statements
regarding the Company’s collaboration with the Abramson Cancer
Center at the University of Pennsylvania and whether it will
advance the understanding of cancer biology or foster innovative
science in immunotherapy - contain predictions, estimates and other
forward-looking statements. These forward-looking statements are
based on the Company’s current expectations and subject to risks
and uncertainties that may cause actual results to differ
materially, including unanticipated developments and the risks
related to the efficacy or safety of the Company’s development
pipeline, the results of further research and development, the high
degree of risk and uncertainty associated with drug development,
clinical trials and regulatory approval processes, other market or
economic factors and competitive and technological advances; and
other risks detailed from time to time in the Company’s reports
filed with the Securities and Exchange Commission, including its
Form 10-K for the year ending December 31, 2016. Incyte disclaims
any intent or obligation to update these forward-looking
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170223005356/en/
Incyte CorporationMediaCatalina Loveman, +1
302-498-6171cloveman@incyte.comorInvestorsMichael Booth,
DPhil, +1 302-498-5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024